Development of New Monoclonal Antibodies against Cytotoxic T-Lymphocyte Antigen-4

IF 0.6 4区 材料科学 Q4 CRYSTALLOGRAPHY
A. V. Demyanov, L. A. Garaeva, E. V. Sergeeva, A. V. Nikitina, E. D. Putevich, S. S. Emelianova, A. S. Spitsyna, L. A. Solomina, A. S. Potyseva, A. V. Volnitskij, A. M. Solianik, Zh. Yu. Sidorova, A. V. Zhahov, V. S. Burdakov, N. A. Verlov, V. V. Kvanchiani, A. L. Konevega, T. A. Shtam
{"title":"Development of New Monoclonal Antibodies against Cytotoxic T-Lymphocyte Antigen-4","authors":"A. V. Demyanov,&nbsp;L. A. Garaeva,&nbsp;E. V. Sergeeva,&nbsp;A. V. Nikitina,&nbsp;E. D. Putevich,&nbsp;S. S. Emelianova,&nbsp;A. S. Spitsyna,&nbsp;L. A. Solomina,&nbsp;A. S. Potyseva,&nbsp;A. V. Volnitskij,&nbsp;A. M. Solianik,&nbsp;Zh. Yu. Sidorova,&nbsp;A. V. Zhahov,&nbsp;V. S. Burdakov,&nbsp;N. A. Verlov,&nbsp;V. V. Kvanchiani,&nbsp;A. L. Konevega,&nbsp;T. A. Shtam","doi":"10.1134/S1063774524602892","DOIUrl":null,"url":null,"abstract":"<p>A promising strategy for cancer immunotherapy involves blocking the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signaling pathway to enhance the antitumor activity of lymphocytes. This method is based on using drugs that interfere with proteins that suppress immune responses in the human body. CTLA-4 is a key protein involved in regulating the immune response, and it is a homolog of the CD28 receptor that is also involved in activating T cells. CTLA-4 can negatively regulate signaling in T cells by competing with the CD28 co-stimulatory ligand. CTLA is expressed on T regulatory cells (Tregs), indicating its importance in both direct and indirect immune suppression by Tregs. Developing monoclonal antibody preparations that block CTLA-4 represents an urgent task for developing new antitumor therapies. These molecules provide a promising foundation for developing theranostic radiopharmaceuticals, which can be used for both diagnosing and treating malignant tumors. In this article, we describe the development process and outcomes of in vitro and in vivo studies on a novel monoclonal antibody targeting human CTLA-4.</p>","PeriodicalId":527,"journal":{"name":"Crystallography Reports","volume":"69 1 supplement","pages":"S38 - S45"},"PeriodicalIF":0.6000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Crystallography Reports","FirstCategoryId":"88","ListUrlMain":"https://link.springer.com/article/10.1134/S1063774524602892","RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CRYSTALLOGRAPHY","Score":null,"Total":0}
引用次数: 0

Abstract

A promising strategy for cancer immunotherapy involves blocking the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signaling pathway to enhance the antitumor activity of lymphocytes. This method is based on using drugs that interfere with proteins that suppress immune responses in the human body. CTLA-4 is a key protein involved in regulating the immune response, and it is a homolog of the CD28 receptor that is also involved in activating T cells. CTLA-4 can negatively regulate signaling in T cells by competing with the CD28 co-stimulatory ligand. CTLA is expressed on T regulatory cells (Tregs), indicating its importance in both direct and indirect immune suppression by Tregs. Developing monoclonal antibody preparations that block CTLA-4 represents an urgent task for developing new antitumor therapies. These molecules provide a promising foundation for developing theranostic radiopharmaceuticals, which can be used for both diagnosing and treating malignant tumors. In this article, we describe the development process and outcomes of in vitro and in vivo studies on a novel monoclonal antibody targeting human CTLA-4.

Abstract Image

抗细胞毒性t淋巴细胞抗原-4单克隆抗体的研制
阻断细胞毒性t淋巴细胞相关抗原-4 (CTLA-4)信号通路以增强淋巴细胞的抗肿瘤活性是一种很有前景的癌症免疫治疗策略。这种方法是基于使用药物来干扰抑制人体免疫反应的蛋白质。CTLA-4是参与调节免疫反应的关键蛋白,它是CD28受体的同源物,CD28受体也参与激活T细胞。CTLA-4可以通过与CD28共刺激配体竞争来负向调节T细胞中的信号。CTLA在T调节性细胞(Tregs)上表达,表明其在Tregs的直接和间接免疫抑制中具有重要作用。开发阻断CTLA-4的单克隆抗体制剂是开发新的抗肿瘤疗法的紧迫任务。这些分子为开发治疗性放射性药物提供了良好的基础,可用于恶性肿瘤的诊断和治疗。在本文中,我们描述了一种新的靶向人CTLA-4的单克隆抗体的开发过程和体外和体内研究的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Crystallography Reports
Crystallography Reports 化学-晶体学
CiteScore
1.10
自引率
28.60%
发文量
96
审稿时长
4-8 weeks
期刊介绍: Crystallography Reports is a journal that publishes original articles short communications, and reviews on various aspects of crystallography: diffraction and scattering of X-rays, electrons, and neutrons, determination of crystal structure of inorganic and organic substances, including proteins and other biological substances; UV-VIS and IR spectroscopy; growth, imperfect structure and physical properties of crystals; thin films, liquid crystals, nanomaterials, partially disordered systems, and the methods of studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信